Last reviewed · How we verify
Tc-99m Pentetate
Tc-99m Pentetate is a radiopharmaceutical that binds to transferrin in the blood and is filtered by the kidneys, allowing visualization of renal function and urinary tract anatomy via nuclear imaging.
Tc-99m Pentetate is a radiopharmaceutical that binds to transferrin in the blood and is filtered by the kidneys, allowing visualization of renal function and urinary tract anatomy via nuclear imaging. Used for Renal imaging and assessment of glomerular filtration rate, Detection of renal obstruction and urinary tract imaging, Evaluation of renal transplant function.
At a glance
| Generic name | Tc-99m Pentetate |
|---|---|
| Sponsor | NYU Langone Health |
| Drug class | Radiopharmaceutical diagnostic agent |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging / Nuclear Medicine |
| Phase | FDA-approved |
Mechanism of action
Tc-99m Pentetate (diethylenetriaminepentaacetic acid labeled with Technetium-99m) is a chelate complex that behaves as a freely filtered agent by the glomerulus. It does not bind to plasma proteins significantly and is rapidly cleared by the kidneys, making it ideal for assessing glomerular filtration rate, renal perfusion, and collecting system drainage. The gamma emissions from Tc-99m allow real-time imaging of renal function and detection of obstruction or impairment.
Approved indications
- Renal imaging and assessment of glomerular filtration rate
- Detection of renal obstruction and urinary tract imaging
- Evaluation of renal transplant function
Common side effects
- Minimal systemic adverse events (diagnostic agent with low toxicity)
- Radiation exposure (from Tc-99m decay)
Key clinical trials
- Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones (PHASE1)
- Repurposing Tilmanocept for Cardiac Sarcoidosis (PHASE2)
- Pharmacokinetics, Safety, and Lung Deposition of 99mTc-DTPA Delivered Via the EDDIS System in Healthy Volunteers (PHASE1)
- Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial (PHASE2)
- Advanced Diffusion Imaging in Renal Cancer Patients (NA)
- An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS) (PHASE1)
- Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA (PHASE3)
- Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tc-99m Pentetate CI brief — competitive landscape report
- Tc-99m Pentetate updates RSS · CI watch RSS
- NYU Langone Health portfolio CI